drugset
drugset / Trial / NCT06063291

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

NCT06063291 ↗

Phase 1 Completed 36 enrolled IlDong Pharmaceutical Co Ltd YUNOVIA CO.,LTD. · collab
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of ID110521156 in healthy adult subjects. This is the first clinical study of ID110521156.

Timeline

Start
2023-11-20
Primary completion
2024-07-11
Completion
2024-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ID110521156 Unknown — Oral

Indications

No indication recorded.